Emerging specialty pharmaceuticals company focusing its efforts on the clinical development of new therapies for dyslipidemia
- Year invested 2011
- Investment Stage Early
- Sectors
- Investment Status Historic
- Website omthera.com
- Company Status IPO/Acquired (by Astrazeneca) (NASDAQ: OMTH)